Screener
Halozyme Therapeutics HALO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net income | $379,962 | $283,255 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based compensation | 34,335 | 22,834 |
| Depreciation and amortization | 8,676 | 5,427 |
| Amortization of intangible assets | 59,024 | 35,524 |
| Amortization of debt discount | 4,499 | 3,698 |
| Accretion of premium on marketable securities, net | (632) | (2,843) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's stock-based comp?
- Halozyme Therapeutics (HALO) reported stock-based comp of $17.7M in Q2 2026.
- How has Halozyme Therapeutics's stock-based comp changed year-over-year?
- Halozyme Therapeutics's stock-based comp increased by 45.5% year-over-year, from $12.16M to $17.7M.
- What is the long-term trend for Halozyme Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's stock-based comp has grown at a 25.4% compound annual growth rate (CAGR), from $20.82M to $51.57M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Halozyme Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude